Lourdes Felix
About Lourdes Felix
Lourdes Felix (age 57) is an independent director of La Rosa Holdings Corp. (LRHC), appointed April 2024. She serves as Chair of the Audit Committee and is designated the Audit Committee “financial expert” under SEC rules, with 30 years of experience across capital markets, public accounting, SEC/Gaap/SOX compliance, and corporate finance; education includes a B.S. in Accounting (University of Phoenix) and MBA candidacy at Northeastern University’s D’Amore-McKim School of Business .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| BioCorRx Inc. (OTCQB: BICX) | Chief Executive Officer, Chief Financial Officer, Director | Since Oct 2012 | Led SEC filings; finance, budgeting, internal controls expertise |
| BioCorRx Pharmaceuticals Inc. | Founder and President | — | Built subsidiary operations; financial/operational oversight |
External Roles
| Company | Exchange/Ticker | Role | Tenure | Committees/Impact |
|---|---|---|---|---|
| Siyata Mobile Inc. | Nasdaq: SYTA | Independent Director; Audit Chair; Member of Compensation and Nominating & Corporate Governance | Since Oct 2021 | Oversees financial reporting and governance |
| Avalon GloboCare Corp. | Nasdaq: ALBT | Independent Director; Compensation Committee Chair | Since Jan 9, 2023 | Leads executive pay oversight |
| BioCorRx Inc. | OTCQB: BICX | CEO, CFO, Director | Since Oct 2012 | Executive leadership; SEC compliance |
Board Governance
- Committee assignments: Audit Committee Chair; member of Compensation and Nominating & Corporate Governance Committees; Audit Committee members are Felix, Siegel, and Alavi; all three committees are composed entirely of independent directors .
- Independence: Board determined Felix to be independent under Nasdaq rules and Rule 10A-3; LRHC is a “controlled company” (CEO holds super-voting preferred shares) but currently maintains a majority of independent directors and independent committees, which can change at any time under Nasdaq exemptions .
- Meetings: In FY2024, Board met 5 times and Audit Committee met 4 times; individual director attendance rates are not provided .
- Insider trading policy: Adopted Oct 2025; prohibits pledging/margin accounts, hedging, short selling, and options trading by directors, officers, employees—supportive of alignment and risk control .
Fixed Compensation
| Component | Amount | Frequency/Period | Notes |
|---|---|---|---|
| Non-employee director cash retainer | $12,000 | Per quarter | For Board service |
| Audit Committee Chair cash fee | $3,750 | Per quarter | Role-based incremental fee |
| Compensation Committee Chair cash fee | $3,000 | Per quarter | Not applicable to Felix |
| Nominating & Corporate Governance Chair cash fee | $3,000 | Per quarter | Not applicable to Felix |
| Lourdes Felix – 2024 Fees Earned | $44,450 | FY2024 | Joined Apr 19, 2024; paid cash only (no equity/options) |
Performance Compensation
| Item | 2024 | Vesting | Performance Metrics |
|---|---|---|---|
| Stock awards to Felix | $0 | — | Not disclosed for directors |
| Option awards to Felix | $0 | — | Not disclosed for directors |
- Director equity: Compensation Committee may award options or other equity to non-employee directors in the future using market/peer analyses; no director stock or option awards were reported for Felix in 2024 .
Other Directorships & Interlocks
| Relationship Type | Counterparty | Nature | Conflict/Interlock Assessment |
|---|---|---|---|
| External public company directorship | Siyata Mobile (SYTA) | Audit Chair; member of comp/nom-gov | No LRHC-related transactions disclosed; minimal direct conflict |
| External public company directorship | Avalon GloboCare (ALBT) | Compensation Chair | No LRHC-related transactions disclosed; minimal direct conflict |
| External public company executive | BioCorRx (BICX) | CEO/CFO/Director | Sector unrelated to LRHC’s real estate brokerage; minimal direct conflict |
- Related-party transactions: LRHC disclosed multiple related-party dealings involving the CEO/family; no related-party transactions involving Felix were disclosed .
Expertise & Qualifications
- Audit Committee “financial expert” under SEC rules; financially literate and experienced in finance/accounting (GAAP, SEC, SOX), internal controls, and risk oversight .
- Education: B.S. in Accounting (University of Phoenix); MBA candidate (Northeastern University, D’Amore-McKim) .
- Skills: Capital markets, public accounting, SEC filings, corporate operations, budgeting, internal controls; supports audit oversight and governance .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Common | Notes |
|---|---|---|---|
| Lourdes Felix | 600 | <1% | No pledging disclosed; company policy prohibits pledging/margin/hedging |
- Ownership guidelines: The proxy does not specify director stock ownership guidelines or compliance status; director ownership appears modest relative to outstanding shares .
Governance Assessment
-
Positives
- Independent director; Audit Committee Chair and SEC-designated “financial expert”—enhances oversight of financial reporting and related-party reviews .
- Committees (Audit, Compensation, Nominating) composed entirely of independent directors; strong structural governance despite controlled-company status .
- Insider trading policy prohibitions on pledging, hedging, and short selling reduce misalignment risk .
- No Section 16(a) late filing issues were noted for Felix in 2024–2025 disclosures .
-
Concerns/RED FLAGS
- Controlled company: CEO’s super-voting preferred stock enables unilateral control; board could utilize Nasdaq controlled-company exemptions at any time, potentially weakening independence protections .
- Company-level related-party transactions concentrated with CEO/family (leases, consulting, acquisitions); while not involving Felix, they elevate audit oversight demands and investor scrutiny .
- Equity plan repricing authority: Compensation Committee can reprice options without shareholder approval—shareholder-unfriendly feature; warrants close monitoring of director oversight of equity practices .
- Ownership alignment: Felix’s disclosed ownership (600 shares) is modest; no director stock ownership guidelines are disclosed, limiting formal alignment expectations .
- Time-commitment risk: Concurrent executive role (CEO/CFO of BioCorRx) and multiple public boards may pose capacity constraints; emphasizes need to track attendance and engagement (individual attendance not disclosed) .
-
Engagement/Attendance
- Board met 5 times and Audit Committee 4 times in FY2024; individual attendance rates for directors are not disclosed, limiting assessment of engagement .